Quantcast

Pot-based prescription drug could receive FDA approval

By Muriel Kane
Sunday, January 22, 2012 19:28 EDT
google plus icon
A medical marijuana shop's window sign. Photo: Wikimedia commons.
 
  • Print Friendly and PDF
  • Email this page

A British pharmaceutic firm is completing clinical trials of a drug derived directly from marijuana and hopes to receive approval to market it from the Food and Drug Administration by the end of 2013.

The drug, which contains both THC and cannabidiol, has already been approved in Canada, New Zealand, and several European countries to relieve muscle spasms associated with multiple sclerosis. In the US, however, it would be sold to relieve cancer pain.

The FDA began approving drugs based on synthetic equivalents of the active ingredients in marijuana in 1985, but this would be the first drug derived from the plant itself. This is significant because, as the Associated Press points out, “The U.S. Drug Enforcement Administration categorizes pot as a dangerous drug with no medical value, but the availability of a chemically similar prescription drug could increase pressure on the federal government to revisit its position.”

“There is a real disconnect between what the public seems to be demanding and what the states have pushed for and what the market is providing,” the president of the International Cannabinoid Research Society told the AP. “It seems to me a company with a great deal of vision would say, `If there is this demand and need, we could develop a drug that will help people and we will make a lot of money.’”

Some marijuana advocates, however, worry that government approval of marijuana-based prescription drugs could become a new argument against legalization of medical marijuana. “That’s the race against time,” Kris Hermes of Americans for Safe Access told AP, “in terms of how quickly can we put pressure on the federal government to recognize the plant has medical use versus the government coming out with the magic bullet pharmaceutical pill.”

Photo from Laurie Avocado [CC-BY-2.0 (www.creativecommons.org/licenses/by/2.0)], via Wikimedia Commons

Muriel Kane
Muriel Kane
Muriel Kane is an associate editor at Raw Story. She joined Raw Story as a researcher in 2005, with a particular focus on the Jack Abramoff affair and other Bush administration scandals. She worked extensively with former investigative news managing editor Larisa Alexandrovna, with whom she has co-written numerous articles in addition to her own work. Prior to her association with Raw Story, she spent many years as an independent researcher and writer with a particular focus on history, literature, and contemporary social and political attitudes. Follow her on Twitter at @Muriel_Kane
 
 
 
 
By commenting, you agree to our terms of service
and to abide by our commenting policy.
 
Google+